Novartis India Ltd (EVONILE) is currently trading at 1,700.20 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Evonile Pharma Limited is a 100% India-focused branded-pharmaceuticals company operating an asset-light model through its own therapy-aligned field force, CFAs and stockists. Its portfolio spans cardiology, pain management, gynaecology, wellness, neuroscience, transplant and newly added ophthalmology, with legacy brands marketed directly after transitioning away from a partner-led distribution model. The company is undergoing a fundamental business-model transition from dependence on a single customer to an independent commercial platform. More than 20 CFAs and 2,000 stockists have been onboarded, while an in-house sales and marketing organization is being built, creating near-term disruption but potentially improving control, availability and brand monetization. Q2 FY27 revenue declined 38% year-on-year to ₹56.1 crore, while H1 revenue fell 10% to ₹159.9 crore. The decline reflects a one-time transition correction, including the loss of ₹41 crore of prior-year partner sales, partly offset by ₹7 crore of incremental in-house division sales. H1 FY27 reported a ₹45.3 crore loss after tax compared with ₹51.8 crore profit previously, primarily because of ₹68.3 crore exceptional items, transition costs, higher employee expenses, acquisition-related amortization and finance costs. Excluding some exceptional effects, adjusted operating EBITDA remained positive at ₹18.5 crore for H1. Evonile Pharma Limited retains substantial brand equity, with six brands generating more than ₹30 crore each and several flagship products ranked first in their covered markets. However, the investment case depends on rebuilding availability, restoring prescriber engagement, completing organizational investment and converting legacy demand into sustainable above-market growth.

Over the past 52 weeks, Novartis India Ltd has traded between a low of ₹750.00 and a high of ₹2,588.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Novartis India Ltd has a market capitalization of approximately 4,246.45. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Novartis India Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -1064.27 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 4,246.45 Cr, Novartis India Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Novartis India Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Novartis India Ltd is -1064.27. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Evonile Pharma acquired India-registered trademarks related to a cardiology brand and certain related intellectual-property rights from Pfizer Inc., USA and Pfizer Products Inc., USA. The agreements were executed on September 7, 2026. Evonile Pharma capitalised Rs 1,290 crore, including Rs 40 crore of stamp duty, as intangible assets.

Evonile Pharma reported a Rs 77.54 crore loss for the quarter ended September 30, 2026. This compared with a Rs 32.21 crore profit in the June 2026 quarter and a Rs 24.22 crore profit in the September 2025 quarter.

Evonile reported a Rs 77.5 crore loss after tax in Q2 FY27 after recording Rs 68.3 crore of exceptional items and Rs 15.4 crore of one-time expenses. Revenue also declined 38% year on year to Rs 56.1 crore during the distribution-model transition.

Evonile says the majority of its sales had been concentrated with one customer under its earlier model. It is moving to direct sales to stockists to support legacy brands that had been sold through partner-led, outsourced distribution.